The £400 million ($529 million) investment programme pledged as part of the new voluntary system of rebates paid by pharma companies in the UK has been announced and will focus mainly on su
AstraZeneca has said it has "no idea" where rumours of a plan to relocate a planned facility in the UK to the US have come from, adding: "They do not seem to be based on facts."
The UK drugs regulator has approved Eisai and Biogen's Alzheimer's disease therapy Leqembi, shortly after an EU committee turned it down on the grounds that its modest efficacy did not outw
AstraZeneca's plan to invest £450 million ($578 million) in a vaccines manufacturing plant in the UK has been thrown into doubt, claims a report in the Financial Times.
The list of UK biotechs deciding to abandon listings on the AIM exchange in the UK just lengthened, after BiVictriX said it wants to cancel its shares and go private.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.